Dark Blue Therapeutics
London, GB · Founded 2020 · 13 employees on LinkedIn · 1 known investors
Dark Blue Therapeutics develops novel medicines for cancer through integrated drug discovery combining internal expertise with academic partnerships. The company focuses on identifying transformative therapeutic approaches across multiple cancer mechanisms.
Founders & leadership
AM
Alastair MacKinnoninChief Executive Office Dark Blue Therapeutics
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- DARK BLUE THERAPEUTICS LTD
- Company number
- 12645831
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 4 Jun 2020
- Registered office
- Hayakawa Building, Edmund Halley Road, The Oxford Science Park, Oxford, OX4 4GB
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 30 Jun 2025 · next due 30 Sept 2026
- Confirmation statement
- last made up to 3 Jun 2026 · next due 17 Jun 2027
Current officers · 2
- Russell James Abberley — director, appointed 30 Dec 2025
- Binakumari Sanjay Patel — director, appointed 8 Jun 2026
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Dark Blue Therapeutics do?
- Dark Blue Therapeutics develops novel medicines for cancer through integrated drug discovery combining internal expertise with academic partnerships. The company focuses on identifying transformative therapeutic approaches across multiple cancer mechanisms.
- Who are Dark Blue Therapeutics's investors?
- Dark Blue Therapeutics's investors include Oxford Science Enterprises.
- Where is Dark Blue Therapeutics headquartered?
- Dark Blue Therapeutics is headquartered in London, GB.